Diseases of the Esophagus
P1.101. Treatment Selection and Real-World Outcomes of First-Line ICI-Based Therapy for Unresectable or Recurrent Esophageal Cancer in a Regional Hospital
Abstract Topic Esophageal Cancer: Management of Metastatic Cancer Background Based on pivotal clinical trials, immune checkpoint inhibitors (ICIs) have demonstrated efficacy in patients with unresectable advanced or recurrent esophageal cancer and are now incorporated as standard treatment in the Japanese clinical practice guidelines. Although expanded therapeutic options are expected to improve survival outcomes, real-world data remain limited. Our institution is a regional hospital where a large proportion of pat …